TuHURA Biosciences to Present Its IFx-2.0 Personalized Cancer Vaccine Clinical Trial Results at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting [Yahoo! Finance]
Kintara Therapeutics, Inc. (KTRA)
Company Research
Source: Yahoo! Finance
developing novel technologies to overcome resistance to cancer immunotherapy, today announced that its IFx-2.0 Phase 1b clinical trial results have been accepted for poster presentation at the 2024 ASCO Annual Meeting taking place May 31-June 4, 2024 in Chicago, IL. Details of the presentation are as follows: Title: Phase 1b trial of IFx-Hu2.0, a novel in situ cancer vaccine, in checkpoint inhibitor-resistant Merkel Cell Carcinoma (MCC) and Cutaneous Squamous Cell Carcinoma (cSCC) Abstract #: Presenter: Andrew Brohl, MD, H. Lee Moffitt Cancer Center and Research Institute Session Title: Melanoma/Skin Cancers Session Date and Time: Saturday, June 1, 2024 at 1:30 PM CDT Location: Hall A, Poster #376 TuHURA recently announced it has entered into a definitive agreement for an all-stock transaction with Kintara Therapeutics, Inc. ("Kintara") to form a company combining expertise and resources to advance a risk diversified late-stage oncology pipeline. In conjunction with th
Show less
Read more
Impact Snapshot
Event Time:
KTRA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
KTRA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
KTRA alerts
High impacting Kintara Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
KTRA
News
- STOCKHOLDER INVESTIGATION: The M&A Class Action Firm Announces an Investigation of Kintara Biopharma, Inc. - KTRAPR Newswire
- SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates MODN, SCX, KTRAPR Newswire
- Lifshitz Law PLLC Announces Investigations of KTRA, CHX, PIK, and LABPAccesswire
- KINTARA THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Kintara Therapeutics, Inc. - KTRABusiness Wire
- Shareholder Alert: Ademi LLP investigates whether Kintara Therapeutics, Inc. has obtained a Fair Price in its transaction with TuHURAPR Newswire
KTRA
Sec Filings
- 4/25/24 - Form 425
- 4/25/24 - Form 8-K
- 4/3/24 - Form 425
- KTRA's page on the SEC website